Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
| 대상 질환 | Gastric Adenocarcinoma, GastroEsophageal Cancer |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | University of California, Irvine |
| 상태 | 완료 |
| 참여자 수 | 34 명 |
| 중재(약물) | Cabozantinib, Pembrolizumab |
| 시작일 | 2020년 2월 4일 |
| 완료일 | 2023년 11월 25일 |
| 결과 공개일 | 2025년 8월 11일 |
요약
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who have progressed, or not tolerated, at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Percentage of Participants With Progression-free Survival at 6 Months
| Cabozantinib and Pembrolizumab | 6 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Ad — Hoffmann-La Roche
- Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patient — National Cancer Institute (NCI)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)
- Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Un — University of Southern California
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresecta — National Cancer Institute (NCI)
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients — National Cancer Institute (NCI)